Five Prime Therapeutics Prices Public Offering of Common Stock

Five Prime Therapeutics Prices Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Five Prime
Therapeutics, Inc. (Nasdaq:FPRX) announced today the pricing of an
underwritten public offering of 3,000,000 shares of its common stock at a
price of $12.50 per share for an aggregate offering of $37.5 million, before
underwriting discounts, commissions and estimated expenses. All of the shares
of common stock are being offered by Five Prime. In addition, Five Prime has
granted the underwriters a 30-day option to purchase up to 450,000 additional
shares of common stock at the offering price. The offering is expected to
close on February 12, 2014, subject to customary closing conditions.

Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC are acting
as joint book-running managers and Guggenheim Securities, LLC is acting as a
co-manager for the offering.

A registration statement related to the common stock being offered by Five
Prime was declared effective by the Securities and Exchange Commission on
February 6, 2014. The offering is being made only by means of a final
prospectus, which is part of the effective registration statement. Copies of
the final prospectus, when available, may be obtained by contacting Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,
12^th Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail:; or BMO Capital Markets, Attention: Equity
Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800)
414-3627, e-mail:; or Wells Fargo Securities, LLC,
Attention: Capital Markets Client Support, 1525 West W.T. Harris Boulevard,
NC0675, Charlotte, NC 28262, telephone: (800) 326-5897, e-mail:

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

About Five Prime Therapeutics, Inc.

Five Prime is a clinical-stage biotechnology company focused on discovering
and developing novel protein therapeutics for cancer and inflammatory
diseases. Five Prime has developed a library of more than 5,700 human
extracellular proteins. Five Prime screens this comprehensive library with its
proprietary high-throughput protein screening technologies to identify new
targets for protein therapeutics.

         Amy Kendall
         Corporate Communications

Five Prime Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.